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Executive Summary 
People living with an opioid use disorder in Canada should have access to comprehensive treatment 
options that meet all their needs. Best Practices across the Continuum of Care for the Treatment of 
Opioid Use Disorder presents services that should be available to individuals experiencing or at risk of 
experiencing harms from opioid use.  
This report, developed to inform Health Canada’s Federal, Provincial and Territorial Treatment Task 
Group, outlines the standard of service that should implemented to provide person-centred care to all 
people experiencing harms from opioids. The report includes a summary of actions taking place 
across Canada at multiple levels of government to help people experiencing harms from opioids and 
to stop the deaths occurring from opioid poisonings. 
The Continuum of Care  
Every person’s pathway through the continuum of care may look different. The components can 
overlap and are most effective when used together. Some people may use all services in the 
continuum of care whereas others might not. There are also people who might revisit different 
components as needed. Detailed descriptions of each element are in the full report.  
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Key Findings 
Throughout the treatment process, there are fundamental principles and best practices to take into 
consideration. The first principle is that the person living with an opioid use disorder should determine 
the goals of their treatment with support from an experienced care provider. Other principles include: 
 Customize a treatment plan to meet the individual’s’ needs and goals.  
 Continually assess the person’s well being for any issues that could prevent successful outcomes, 
including physical and mental health, stress, housing concerns, financial barriers and so on. 
 Provide services that are culturally competent and safe. 
 Provide services that are trauma and gender informed. 
 All efforts should be made to reduce stigma, which is a major barrier to seeking treatment and 
maintaining recovery.  
 Peer-engaged and led services establish trust and help people sustain positive changes in their 
substance use.  
 Make recovery the focus of policies and practices, which can enhance outcomes for people seeking 
treatment.    
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Introduction 
Evidence-informed comprehensive treatment is known to improve the lives of those living with an 
opioid use disorder. This inventory was developed in response to a commitment to the Health Canada’s 
Treatment Task Group to “develop a document that defines the continuum of outreach, interventions 
and treatment supports for opioid use disorder, including rapid access to addictions medicine and 
mild to moderate social supports (i.e., brief intervention and counselling), [and] make recommendations 
on best practices and drive policy development to improve quality care across the country.”  
Identification of best practicesi across the continuum of care can provide a benchmark to ensure 
effective services are available in Canada to prevent and minimize the experience of harms.ii 
Responding to these harms requires a combination of both available services and quality 
implementation. This inventory includes best practices for certain services, but also overarching 
principles that should guide the way in which these services are delivered (i.e., in a patient-centred 
manner).  
The continuum of care outlined below was developed to inform Health Canada’s Treatment Task 
Group of the services to be considered for availability in all jurisdictions. It should be recognized that 
the settings and providers for the services outlined in the continuum might differ across and within 
jurisdictions. For example, a range of practitioners from nurses to pharmacists to community 
outreach and peer support workers can implement harm reduction services, whereas 
pharmacological interventions might require a specialized addiction physician. Additionally, 
pharmacological interventions might take place in a primary care provider’s office or in a specialized 
opioid agonist treatment clinic. System planning is required to ensure that quality services are 
available and competent providers are engaged to meet the needs and intensity levels of those 
seeking help.  
While reviewing the findings, the reader should consider that the evidence base related to substance 
use treatment is an evolving area of inquiry. Many components of practice are guided by expert opinion 
and even best practices are established based on varying strengths of evidence.  
Method 
Best practices for care and treatment of opioid use disorder among the general population were 
identified from peer-reviewed and grey literature. Peer-reviewed articles were found through 
searches using PubMed, PsycNet, Health Evidence and the Cochrane Library. Grey literature was 
retrieved by searching the Centre for Addiction and Mental Health’s Google Custom page as well as 
individual websites such as the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
Best Practices Portal, HealthEvidence.org, Public Health England and Portico. A search using Google 
was also performed to ensure that valid resources were not omitted. A limitation of this methodology 
is that 1) the quality assessment of the peer-reviewed literature was not within scope for this project 
and 2) that grey literature is not necessarily peer reviewed and can have varying levels of quality. 
Retrieving resources from only reputable, well-established organizations minimized this risk.  
                                                 
i Best practices are defined as initiatives, projects, policies, programs or procedures that are recognized or accepted, and have proven 
effective in achieving the desired outcomes or results. 
ii Throughout this documents the term “harm” can refer to a variety of outcomes, including injury, contraction of illnesses such as hepatitis 
C or HIV, functional impairments, polysubstance use, dependency, overdose, poisoning, or risk of overdose with relapse following a period 
of abstinence. 
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To focus on best practices, as opposed to emerging ideas, only review papers, systematic reviews, 
meta-analysis and grey literature produced between 2007 and 2018 were included. Primary 
research and preclinical studies were excluded. The release by the Canadian Research Initiative in 
Substance Misuse of guidelines coincided with the development of this inventory. To avoid 
duplication of efforts, in-depth reviews of pharmacological or psychosocial interventions were not 
conducted. A detailed search strategy is available upon request.  
Best practices that speak to specific populations (i.e., youth, women who are pregnant, First Nations, 
individuals living with chronic pain and individuals convicted of an offense) are highlighted in 
Appendix A, where studies with these populations appeared in general searches. Studies examining 
individuals living with cancer pain were excluded. While it is critical to tailor treatment to the needs of 
specific groups, a comprehensive search for each population was out of scope for this project. 
Additionally, interventions for individuals who use drugs occasionally requires a separate, in-depth 
review as the strategies that are effective for this population could differ from those that are best 
practices to treat individuals living with an opioid use disorder. 
Best practices were synthesized in the inventory to highlight critical services across the continuum of 
care. External partners with expertise in addiction medicine, harm reduction, substance use, 
psychology and psychiatry reviewed and provided input to the inventory. (See Appendix B for details.) 
The Continuum of Care for the Treatment of Opioid Use 
Disorder  
The continuum of care represents a range of services that should be available to individuals 
experiencing or at risk for experiencing harms from opioid use. Although presented as discrete 
categories, many of the continuum components overlap in practice (e.g., screening and assessment) 
and are most effective when used together. Pathways through the continuum are not necessarily 
meant to be linear. Some individuals might use all components of the continuum whereas others 
might not, and some might revisit different components as needed.1,2,3,4,5 
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*Although there is insufficient evidence (i.e., no review papers) to categorize rapid access clinics or 
community outreach as best practices in the continuum of care, details about these components 
were included as a) these resources have shown promise in Ontario,6 and b) to address the request 
from Health Canada to identify services that might be of value to individuals who use drugs 
occasionally or are not identified in health surveillance activities. 
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Best Practices for the Continuum of Care 
This inventory outlines best practices for each component of the continuum; however, there are 
overarching principles to be considered in implementing any of the services in the continuum.  
1. The individual experiencing harm from opioid use should determine the ultimate goal of 
treatment (i.e., safer use, abstinence, opioid maintenance, obtaining certain functional 
outcomes, etc.) with input from a care provider who is experienced in substance use 
management.1 
2. The treatment plan and services used can be determined together with the individual, and 
customized to meet their needs and goals.1,2,7,8,9,10,11 Stepped care, wherein the least 
intensive services are offered first, should be used.5,12,13  
3. The continuum of care should assess and address in a coordinated manner all components 
of a person’s wellbeing that might prevent successful outcomes, including physical and 
mental health, personal vulnerabilities, stressors, housing, recovery capitaliii and so 
on.1,2,3,4,7,9,11,12,13,14,15,16,17,18,19,20,21,22,23 Family of choice can also be included in treatment 
activities where desired by the individual seeking treatment.2,9  
4. Services should be culturally competent and safe, and trauma and gender 
informed.1,10,12,20,21 
5. Stigma is a major barrier to seeking treatment and maintaining recovery. All efforts to reduce 
stigma should be undertaken.2,20 
6. Peer-engaged and peer-led services help establish trust20,24 and help individuals sustain 
positive changes in substance use.2  
7. A recovery-oriented system of care, wherein policies and practices that reflect recovery 
principles are integrated into treatment, can enhance outcomes for individuals seeking 
treatment.2  
Harm Reduction 
Efforts to minimize the negative outcomes experienced while an individual is using opioids and to 
prevent accidental death or poisoning should be integrated along the continuum of care.5,12 
 Education and training on recognizing and responding to overdose, along with take-home 
naloxone, decreases mortality related to opioid overdose.10,25,26,27,28,29 Take-home naloxone 
should be widely available,7,8,16,19 particularly to individuals being treated for an opioid use 
disorder, as well as to those who frequently spend time with them as they may be present if an 
individual overdoses.5,7,12,30 
 Supervised consumption services help prevent multiple harms, including overdose,20,31,32 and 
provide an opportunity to connect with health and other support services, including primary 
care32 and treatment.31,33 
 Needle distribution and exchange programs are related to decreased incidences of HIV;34,35,36 
results related to incidences of hepatitis C have been mixed as sharing of other drug use 
                                                 
iii Recovery capital refers to the resources an individual can rely on to support them through their journey along the continuum. It may 
include personal, interpersonal and community resources.2  
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equipment such as swabs, cookers, water and filters, is also a factor of particular importance in 
the transmission of HCV.34,37 
Resources 
A Public Health Guide to Developing a Community Overdose Response Plan20 
Best Practice Recommendations for Canadian Harm Reduction Programs that Provide Service to 
People Who Use Drugs and Are At Risk for HIV, HCV, and Other Harms: Part 138 
Community Management of Opioid Overdose26 
Supervised Consumption Services: Operational Guidance31 
Screening 
Identifying if an individual is currently at risk for experiencing harms from opioid use allows for the 
identification of those who may benefit from additional services and supports.4
 General dialogue for initial screening should be used with all individuals,4 not just those at
risk;1,10 positive screens should be followed with an assessment.4
 Screening should address polysubstance use, and mental and physical health concerns.7,9
 Multiple screening tools are available, as listed below, but are general to all substances and do
not provide comprehensive assessment (i.e., do not address mental health, physical concerns,
etc.). There is no consensus on best practice.39,40
• Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): eight-item measure
that can be used in primary care settings to identify risk related to the use of 10 different
substances across all levels of severity41
• CAGE-Adapted to Include Drugs (CAGE-AID): four-item measure to predict substance use
disorders in primary care context42
• Drug Abuse Screening Test (DAST): 10-, 20- and 28-item versions assess problematic drug
use among multiple populations43
• Global Appraisal of Individual Needs—Short Screener (GAIN-SS): 20-item measure that
examines internalizing and externalizing disorders, substance abuse and criminal
behaviour44
• Kreek-McHugh-Schluger-Kellogg Scale: 28-item measure that considers the frequency,
amount and duration of use of opiates, cocaine, alcohol and tobacco45
• Two-Item Conjoint Screen: two-item measure that can be used in primary care to evaluate
using substances more than intended to and feeling the need to cut down on substance use
in the past year46
Assessment 
Assessment allows for the identification of an opioid use disorder and co-occurring conditions, 
determines the severity and indicates the intensity of treatment to be considered.4  
 The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) is the most
recognized criteria to establish a diagnosis of opioid use disorder.47
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 Assessment should include: 
• concurrent disorders and physical health concerns,1,3,7,9 and 
• an examination of recovery capital, which are the resources an individual has to support 
them through their journey. Treatment should then be designed to build and strengthen 
recovery capital.2  
 Assessment should also include collaborative care planning with the individual seeking 
treatment4 repeated throughout treatment to ensure services are meeting individuals changing 
needs.3,9 
 There are multiple assessment tools, including the Addiction Severity Index (ASI), a structured 
interview that assesses an individual’s functioning or the severity of problems an individual with 
an opioid use disorder is experiencing in the medical, employment, legal, social, psychological 
and substance use components of their lives.48 
Brief Interventions 
Brief interventions provide non-judgmental information regarding the harms of substance use, and 
explore motivation to change opioid use.49,50 The Screening, Brief Intervention and Referral to 
Treatment (SBIRT) framework allows for the identification of individuals who may be experiencing 
harms from substance use. Those who are not experiencing harms receive education and 
reinforcement for their behaviours. Those who are at moderate to high risk of harms receive a brief 
intervention, and those with severe risk or who are currently experiencing harms are referred to 
treatment.50  
 Using motivational interviewing can encourage change towards healthier behaviours1 and reduce 
substance use.10 
 SBIRT typically involves two sessions that are 10–45 minutes in duration49 
Rapid Access Addiction Medicine and Clinics 
Rapid access clinics allow individuals experiencing harms from opioids to receive treatment from an 
addiction specialist (typically within a few days of referral) until they are stabilized. Individuals then 
receive ongoing treatment from community services and/or a primary care provider who may receive 
support, resources and training about addiction management from the addiction clinic staff.6  
 Rapid access to addiction medicine services have resulted in reduced emergency department 
visits, reduced wait times and lessened stigma,6 as well as greater retention in treatment.51 
However, there is insufficient data to determine if this is a best practice to be included in the 
continuum of care.  
Community Outreach 
These supports can take different forms, but are typically services provided in the community to 
individuals who use drugs. Activities can include education, harm reduction resources and referrals 
to services.24 
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 Examination of assertive community treatmentiv revealed improvements in mental health, quality 
of life, housing stability52 and treatment enrollment, but there is a need for further evaluation to 
determine long-term outcomes.10  
 Best practices for substance use outreach programs: gain the trust of individuals who use drugs, 
go to where these individuals are, conduct outreach in evening and early morning (when risk is 
greatest), provide multiple means for behaviour change (e.g., information, equipment, referrals, 
etc.), provide training and supervision for employees, and supports to address burnout, relapse 
and other health issues.24  
Withdrawal Management 
Withdrawal management without subsequent treatment is strongly advised against and can put an 
individual at risk of serious harms, including death, if substance use resumes.3,5,7,10,12,22,23 However, 
pharmacological and psychological supports can help an individual cope with the symptoms 
experienced when they stop using opioids.4  
 If used, an agonist taper should occur slowly over a time period greater than one month.5 
 Methadone,16,23 buprenorphine,5,16,23 and clonidine7,12,23 are recommended to reduce physical 
symptoms of withdrawal. 
 Clinical opiate withdrawal scale (COWS) is used to measure and monitor symptoms.7,53  
 Contingency management and cognitive behavioural therapy were related to greater abstinence 
rates than control conditions over the short term.54 
Resources 
A Guideline for the Clinical Management of Opioid Use Disorder12 
CRISM National Guideline for the Clinical Management of Opioid Use Disorder5 
Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence23 
Medications for Opioid Use Disorder (Treatment Improvement Protocol 63)4 
National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid 
Use7 
The World Federation of Societies of Biological Psychiatry Guidelines for the Biological Treatment of 
Substance Use and Related Disorders. Part 2: Opioid Dependence22 
Pharmacological Interventions 
Medications, particularly opioid agonists, are effective in helping an individual achieve their desired 
recovery outcome.4,5,12,23 
 Internationally, buprenorphine or methadone are the recommended opioid agonist treatments.23  
                                                 
iv Assertive community treatment is define as ‘a service delivery framework characterized by service provision in 
the community, assertive engagement, high intensity of services, small caseloads, 24 h responsibility, team 
approach, multidisciplinary team, close work with support system, and staffing continuity’.53 
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 Within Canada, the Canadian Research Initiative in Substance Misuse developed National 
Guidelines for the Clinical Management of Opioid Use Disorder, which recommend: 
• Buprenorphine/naloxone (bup/nal)v is the recommended first-line medication for most 
individuals in Canada.5,12  
• Methadone can be used as a second-line treatment if bup/nal is not appropriate, or if 
treatment has limitations or is ineffective.5,12  
• Agonist treatment with slow-release oral morphinevi prescribed by an experienced addiction 
physician should be used if first- and second-line treatments are not successful or if there 
are contraindications.5,12  
 For individuals who do not respond well to other pharmacological treatment, diacetylmorphine-
assisted treatment (with or without flexible methadone doses) resulted in greater treatment 
retention and reductions in illicit drug use compared to methadone treatment or baseline 
substance use.16,17,55,56,57,58,59,60 There is a risk of serious events, however, so this treatment 
should only be considered for individuals for whom other treatment options have not been 
successful, and with careful medical supervision.55,59  
 Naltrexone (antagonist) should be considered for those wanting to abstain from opioids.9,23  
 Injected or implanted extended release formulations (naltrexone and buprenorphine) can provide 
improvements to treatment adherence and continuation of care.7,9,15  
 If individuals wish to discontinue medication after prolonged period of successful response to 
treatment (i.e., more than one year), use a slow taper,5 and/or possible use of oral naltrexone.12  
Resources 
A Guideline for the Clinical Management of Opioid Use Disorder12 
CRISM National Guideline for the Clinical Management of Opioid Use Disorder5 
Federal Guidelines for Opioid Treatment Programs9 
Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence23 
National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid 
Use7 
Psychosocial Interventions  
Therapies that can take place in individual, family or group formats can be provided alongside 
pharmacological therapy to help an individual achieve their desired recovery outcome.4,23,49 
 Psychosocial interventions provided together with pharmacological treatment are effective 
approaches to treating opioid use disorder,3,7,23,47,61,62 though it is unclear if certain psychosocial 
therapies are more effective than others,62,63 and if certain modalities correspond better to 
particular medical-treatments.62,64,65  
                                                 
v The buprenorphine/naloxone formulation is commonly referred to by its brand name: Suboxone.  
vi One external reviewer strongly recommends against this approach and believes there is an insufficient evidence base to support the use 
of oral morphine. 
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 Although some studies have shown psychosocial therapies to have no additional benefit over 
pharmacological therapies, authors have rationalized that this occurs because the control groups 
are often receiving some degree of management or support, and thus the question that should 
be examined is if extensive therapies provide benefit over minimal supports.63,66 
• Reviews of cognitive behavioural therapy (CBT; helping individuals reframe their thinking and 
actions10) have revealed mixed results.54 Some mildly support the use of cognitive 
behavioural therapy among those on methadone maintenance treatment;62 others do not 
reveal any reductions in substance use among those in methadone maintenance therapy;49 
and still others show no effect of CBT as compared to those receiving physician management 
of buprenorphine treatment.62 
• Contingency management (CM), where goods or services are provided for negative drug tests 
among those on methadone or naltrexone maintenance treatment,49 have consistently 
demonstrated positive outcomes, including drug-free urine tests, longer involvement in 
treatment and greater functional improvements, as compared to control groups or treatment 
as usual.10,16,23,49,54,62,66 
• Behavioural couples therapy and family training have been associated with opioid abstinence 
and/or reduced illicit drug use.49,62 
• Motivational interviewing and relapse prevention counselling enhance effectiveness of 
pharmacological treatments9 and has been related to decreased self-reported substance use 
as compared to those solely receiving methadone maintenance therapy.62  
 At a minimum, psychosocial needs assessment, supportive counselling, links to existing family 
supports and referrals to community services should be provided to individuals seeking 
treatment.7 
 Concurrent disorders (where an individual experiences both substance use and mental health 
disorders) are very common and evidence-based treatment should address both concerns.3 
Resources 
Federal Guidelines for Opioid Treatment Programs9 
Drug Misuse: Psychosocial Interventions (National Clinical Practice Guideline Number 51)49 
Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence23 
National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid 
Use7 
Recovery, Sustaining Wellness and Ongoing Care 
Recovery can be defined differently by each individual, but generally includes changes to lifestyle 
and behaviours by accessing formal (e.g., treatment programs) and/or informal (e.g., meditation) 
supports to manage or eliminate opioid use and improve multiple aspects of quality of life.2 
 Participation in recovery support services leads to better outcomes than standard treatment 
alone.10  
 The treatment system should be recovery oriented,2,9 which includes recognizing and supporting 
that each individual’s recovery journey might look different and is a personal venture.2 
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 Connections to support services following acute treatment increases recovery capital.2,9 Assess 
recovery capital and aid individuals in strengthening it.2  
Resources 
Federal Guidelines for Opioid Treatment Programs9 
Moving Toward a Recovery-Oriented System of Care: A Resource for Service Providers and Decision 
Makers2 
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Actions across Canadavii 
The federal government has instituted a number of policy changes to ensure Canada is able to 
respond to the needs of those experiencing harms from opioid use. These actions include changes to 
Bill C-37, An Act to Amend the Controlled Drugs and Substances Act and to Make Related 
Amendments to Other Acts, permitting a significant reduction in the number of criteria required to 
apply for an exemption under section 56 of the Act to establish safe consumption sites. Bill C-37 
also amends the Customs Act to allow border security agents to inspect packages less than 30 
grams. Whereas previously the focus was on larger packages, the potency of fentanyl allows small 
volumes in transit to be of concern. It is also illegal now to bring unregistered pill presses into 
Canada, which will make it more difficult for illicit substances to be processed. Finally, amendments 
made by Bill C-37 allow new psychoactive substances to be scheduled and controlled quickly and 
also enables law enforcement to dispose of drugs expediently.  
In the spring of 2017, the parliament of Canada passed the Good Samaritan Drug Overdose Act. This 
act protects individuals experiencing an overdose or present at the scene of an overdose from some 
charges related to the possession of controlled substances. The act is intended to encourage people 
to call emergency services if an overdose is occurring without fear of legal repercussion. Another 
measure to address opioid overdoses is the coverage of injectable and nasal forms of naloxone as 
open benefits for First Nations and Inuit people under the non-insured health benefits program. 
Correctional Services of Canada has developed a national project to provide individuals being 
released from incarceration with access to a take-home naloxone kit. Across Canada, naloxone can 
be obtained at pharmacies without a prescription (without a fee in some areas) for anyone 
concerned about the risk of overdose for themselves or others. 
The Honourable Ginette Petitpas Taylor, Minister of Health, has announced additional actions to 
support an evidence-based response to the opioid crisis. These actions include streamlining the 
processes to set up temporary overdose prevention sites, allowing drug checking to occur at 
supervised consumption sites and researching drug checking further in pilot projects. Projects are 
also examining alternatives to pharmaceutical opioids, such as hydromorphone, to be provided as an 
uncontaminated source to individuals using illicit opioids.  
Significant funding investments have been made in the 2018 budget to address border security, law 
enforcement and stigma, and to support advancements in the evidence base related to the opioid 
crisis, as well as the evaluation of actions taken in response to the crisis. 
The Government of Canada has also amended regulations focusing on treatment for opioid use 
disorder which allow healthcare practitioners to prescribe methadone without a section 56 
exemption and to increase access to diacetylmorphine (prescription-grade heroin) for prescription to 
individuals dependent on opioids. While the federal government is able to make policy changes to 
regulations and has provided $150 million to the provinces and territories to enhance evidence-
based treatment, the individual jurisdictions are responsible for service delivery.    
As the impact of opioid harms is being experienced differently across Canada,67 responses vary in 
each province and territory. The jurisdictions represented on the Treatment Task Group have made 
efforts to prevent the loss of more lives to the opioid crisis. Many jurisdictions are increasing access 
to naloxone. British Columbia, Alberta and Ontario are opening more safe consumption and overdose 
                                                 
vii During the March 12, 2018, Treatment Task Group teleconference it was decided that a summary highlighting the actions taking place 
in each jurisdiction would comprise the second phase contract requirements as opposed to policy analysis.  
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prevention sites. British Columbia is expanding the use of fentanyl test strips to determine the 
contamination of substances and prevent harm to users.  
Efforts have also been made to improve or expand treatment and service options. Almost all 
jurisdictions are working to improve physicians’ knowledge of appropriate opioid prescribing, as well 
as their knowledge of treatments for opioid use disorder. British Columbia and Ontario have 
established clinics that provide rapid access to addiction treatment. Manitoba has made changes to 
its formulary to make access to bup/nal easier, and nurse practitioners in Ontario can now prescribe 
bup/nal. British Columbia and Alberta are initiating the use of hydromorphone as an agonist 
treatment option.  
Public education campaigns are being conducted across the country to combat stigma, to increase 
awareness of the dangers of fentanyl and other opioids, and to educate individuals on how to avoid 
or respond to an overdose. Peer services and supports are being used in British Columbia and being 
considered for implementation in Newfoundland and Labrador. Provinces are also responding to the 
social determinants of health by increasing support for housing.   
Together, these efforts will establish a comprehensive response that addresses the complexities and 
contextual differences of the opioid crisis across Canada. Additional details on the initiatives each 
jurisdiction represented on the Treatment Task Group is taking can be found in Appendix C. 
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Appendix A: Best Practices for Specific Populations 
A literature review was not conducted on the populations identified below. This appendix highlights 
only that information encountered as part of a general search. To determine best practices for these 
populations, an in-depth, targeted literature search and synthesis would need to be completed.  
Screening 
Youthviii 
 Multiple tools are available, but there is no consensus on best practice. 
 Adolescent Alcohol and Drug Involvement Scale (AADIS): interview to determine if 
assessment of alcohol or other drug use is needed68 
 CRAFFT: six-item measure to screen for substance use disorders and related problems69 
 Drug Abuse Screen Test (DAST)—Adolescent: 27-item scale that determines the presence 
and severity of problematic substance use among adolescents43 
 GAIN-SS: 20-item measure that examines internalizing and externalizing disorders, 
substance abuse and criminal behavior44  
 Violence, abuse and risk of suicide should be considered.11 
Individuals living with chronic pain 
 Multiple scales exist to determine risk before initiating or during opioid therapy for chronic 
pain, but there is no consensus on best practice.39,40,70,71,72,73,74 
 Addiction Behaviors Checklist (ABC): 20-item measure to track behaviours related to 
prescription drug addiction75  
 Atluri Screening Tool: 20-item checklist to determine which patients with chronic pain are 
at risk of prescription opioid misuse76 
 Brief Risk Interview (BRI): questions about “past medication use, past discharge from 
treatment, concurrent mental health disorders, current and past substance abuse, family 
history of substance abuse and educational level” can be used by pain clinicians to 
determine risk of aberrant opioid use77  
 Current Opioid Misuse Measure (COMM): 17-item self-report instrument used to measure 
possible opioid misuse among individuals receiving opioid treatment for chronic pain78 
 Diagnosis, Intractability, Risk, Efficacy (DIRE) score: rating scale developed for a primary 
care physician to predict effectiveness of pain medication and appropriate use of long-
term opioid treatment79 
 Opioid Risk Tool (ORT): self-administered instrument examining individual and family 
history of substance use disorders, personal history of preadolescent sexual abuse, and 
                                                 
viii The definition of youth varied across the studies included in this appendix. It should be noted that recommendations differ based on 
the chronological age and developmental stage of youth (i.e., youth, adolescents, transitional-aged youth, young adults, emerging adults, 
etc.).11 
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particular psychological illnesses to determine the level of risk a pain patient has for 
aberrant opioid use80 
 Prescription Drug Use Questionnaire (PDUQ): 42-item interview to be used by clinician to 
evaluate pain, opioid use, social and relationship factors, family and personal history of 
pain, substance use and mental health concerns. Results from the measure should be 
considered in conjunction with input from physicians and family members, and past 
medical charts.81  
 Prescription Opioid Misuse Index (POMI): six-item interview that identifies the risk misuse 
among of individuals using prescription opioids to treat pain82  
 Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R): 24-item self-
report questionnaire “to predict aberrant medication-related behaviors among chronic 
pain patient considered for long-term opioid therapy”83 
 Screening Instrument for Substance Abuse Potential (SISAP): five-item instrument to 
identify individuals at risk of opioid abuse among individuals living with chronic pain to be 
used in conjunction with clinical judgement84 
 Screening Tool for Addiction Risk (STAR): 14 self-administered true or false questions 
that identifies chronic pain patients at risk of problematic opioid use during treatment85 
 Urine screening should be administered to individuals at high risk or who exhibit unexpected 
drug related behaviours.13  
Assessment 
Youth 
 Assessment should be ongoing with movement across the continuum of care as needed.21 
Individuals living with chronic pain 
 Assessment should begin with a detailed history of prior pain and problematic substance 
use, provide weekly urine testing, and encourage reports of opioids prescribed by other 
practitioners.13  
 Pain Assessment and Documentation Tool (PADT): assesses “analgesia, activities of daily 
living, adverse effects and aberrant drug related behaviours”13  
Community Outreach 
Youth 
 Assertive community treatment resulted in improvements in psychiatric symptoms, general 
functioning and reduced duration and frequency of hospital admissions.86  
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Withdrawal Management 
Women who are pregnant 
 Detoxification should be avoided; methadone and buprenorphine are safe for treatment 
during pregnancy.7,22  
Pharmacological Interventions 
Youth 
 Bup/nal should be the first-line opioid therapy for youth, and only opioid therapy for youth 
that live or frequently travel to communities where methadone is not available.87,88  
 Buprenorphine, methadone and naltrexone can be considered for youth.7  
Women who are pregnant 
 Opioid agonist therapy should be initiated or maintained during pregnancy,7,16,87 labour and 
post-natal care.87  
First Nations 
 Bup/nal should be the first line treatment.87  
 Transition from methadone to bup/nal when clinically or geographically indicated.87  
Individuals living with chronic pain 
 Non-narcotic treatment should be considered first.7 Opioid therapy can be considered if the 
benefits of treatment outweigh the potential risks. Treatment should be structured with 
check points to validate progress, and agreed upon actions in the event of non-compliance 
should be endorsed by the individual receiving treatment and all healthcare providers to 
ensure clarity of goals and the course of treatment.13,89  
 Treatment must be comprehensive to address both opioid use disorder and chronic pain 
concerns.13  
Individuals convicted of an offense 
 Pharmacological treatment is recommended and should be accessible.7,23  
 Methadone maintenance therapy initiated before, during or after release was related to 
greater treatment engagement after release, reduced risk of death from overdose, 
decreased relapse and reduced HIV drug-risk behaviours.64  
 Monthly naltrexone injections resulted in lower rates of relapse and greater time to relapse, 
as compared to treatment as usual (brief counselling, referral to community treatment 
programs). However, results were not sustained after treatment ended.90  
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Psychosocial and Behavioural Interventions  
Youth 
 Behavioural therapies focusing on resistance skills, coping, problem-solving and 
interpersonal relationships can strengthen motivation to change and thus help adolescents 
remain abstinent from substance use.11 
 Family (of choice) should be involved in treatment and receive education and counselling as 
needed, including with transitional-aged youth.9,11,21 
First Nations 
 Programs based in community, land and culture.87  
Individuals living with chronic pain 
 Cognitive behavioural therapy and graded exercise recommended.13  
 Education regarding how to deal with pain syndromes without misusing opioids should be 
prioritized.47  
Individuals convicted of an offense 
 Access to psychosocial treatment options should be equivalent to those available in the 
community.49 
Recovery, Sustaining Wellness and Ongoing Care 
First Nations 
 Culturally appropriate aftercare that supports individual, family and community healing from 
post-traumatic stress disorder and historical trauma transmission.87 
Individuals living with chronic pain 
 If relapse occurs, an examination of the factors leading up to the incident should take place, 
followed by a focus on developing coping strategies and supports to address these factors.13   
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Appendix C: Jurisdictional Highlights 
British Columbia 
 In July 2017, the Ministry of Mental Health and Addictions was established with responsibility to 
lead the provincial response to the opioid emergency. An Overdose Emergency Response Centre, 
based on emergency management best practices, was established in December 2017 to bring 
together provincial, health authority, municipal, Indigenous and law enforcement resources to 
tackle the overdose crisis at a community level.  
 The provincial response focuses on four key areas: 
1. Saving lives: Services for people who continue to use drugs that help reduce the risk of 
overdose, reduce the severity of overdose, or provide immediate lifesaving interventions 
when an overdose has happened. 
2. Ending the stigma around addictions and mental illness: Activities that reduce negative 
attitudes about people who use drugs that may keep people from seeking and receiving help 
for problematic substance use. 
3. Rebuilding the network of mental health and addiction treatment services: Services that 
support treatment of and recovery from addiction. 
4. Addressing the full range of supports and social factors: Activities and services that address 
social factors related to substance use such as housing, income, employment, 
intergenerational trauma and community development. 
Saving Lives 
 The province has broadened access to no-cost naloxone with an extensive publicly funded Take-
Home Naloxone program that distributes naloxone kits and community organization facility 
response boxes to over a thousand distribution locations in British Columbia.  
 The province is focusing on drug checking as a harm reduction intervention and has expanded 
drug-checking services through the use of fentanyl test strips to all overdose prevention and 
supervised consumption service locations in the province. The City of Vancouver purchased a 
Fourier-Transform Infrared Spectrometer to rapidly test drug samples at supervised consumption 
sites at Insite and Powell Street Getaway. There is a plan to build upon the City of Vancouver’s 
experience and purchase more mass spectrometers for other health authorities. The BC Centre 
on Substance Use released an evidence review on drug checking services as a harm reduction 
intervention. The report can be found at http://www.bccsu.ca/wp-
content/uploads/2017/12/Drug-Checking-Evidence-Review-Report.pdf   
 The BC Centre for Disease Control has been funded by Health Canada to initiate a pilot project to 
support access to safer drugs. The pilot would dispense oral hydromorphone pills to people who 
use opioids obtained from the illegal drug supply. The pilot is slated to begin in the summer of 
2018.  
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Ending Stigma 
 The province launched an overdose awareness campaign with the Vancouver Canucks in January 
2018. The campaign encourages people to strike up honest conversations about problematic 
substance use with friends, family members, and co-workers. 
 A new website, www.stopoverdoseBC.ca, launched and will continue to expand.  
 The BC Centre for Disease Control, peers and other partners have completed a three-year 
research project, Peer Engagement and Evaluation Project (PEEP). The goal of PEEP is to ensure 
everyone across the province has equal access to harm reduction services by visiting 
communities across B.C. to talk to people who use drugs and providers about peer engagement 
and harm reduction. A number of resources have been developed including a guide for health 
providers that outlines peer engagement principles and best practices. Resources can be found 
at http://www.bccdc.ca/health-professionals/clinical-resources/harm-reduction/peer-
engagement-evaluation#Resources  
Building a Network of Mental health and Addiction Treatment Services  
 The BC Centre on Substance Use has released provincial Guidelines for the Clinical Management 
of Opioid Use Disorder. It is expected that a number of supplementals focusing on the treatment 
of opioid use disorder in pregnancy, in youth, and in correctional settings will be released over 
the next few months. 
 For the small proportion of people who are living with an opioid use disorder and do not respond 
successfully to first line treatment with oral medications (i.e., methadone, 
buprenorphine/naloxone and slow-release oral morphine), the province is working with health 
authorities to expand access to injectable hydromorphone treatment.  
 Regional health authorities are scaling up rapid access to medication treatment for opioid 
addictions by expanding hours of operation and opening new addictions clinics.  
 Increased education and training in addictions treatment has been made available to healthcare 
providers through interdisciplinary addictions fellowships, rural fellowships through the Rural 
Education Action Plan initiative, online addiction medicine and opioid agonist treatment online 
training programs and preceptorships, and a range of clinical guidance documents, provider 
tools and fact sheets available from the BC Centre on Substance Use.  
• In particular, the BC Centre on Substance Use offers a free online certificate course 
targeted at healthcare professionals interested in learning more about providing care to 
patients with substance use disorders. Details can be found at 
https://www.bccsu.ca/about-the-online-addiction-medicine-diploma/ 
• Working in partnership with the University of BC Continuing Professional Development 
Program, the BC Centre on Substance Use offers a Provincial Opioid Addiction Treatment 
Support Program to provide education and information for physicians, nurses, allied 
health professionals and other care providers involved in the treatment of individuals 
with opioid use disorder. The course is free and provides an overview of the provincial 
Opioid Use Disorder Guidelines. Details can be found at 
https://ubccpd.ca/course/provincial-opioid-addiction-treatment-support-program  
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Addressing the Full Range of Supports and Social Factors 
 In May 2017, a Mobile Response Team was established under Health Emergency Management 
BC’s Disaster Psychosocial Support Program. The Mobile Response Team delivers services 
across all regions in the province to front-line providers, including volunteers and peers. Services 
include formal and drop-in sessions, assessments, psychosocial education and training, 
information on how to deal with grief and loss, outreach and referrals, team building and trauma 
responses.  
 The province and regional health authorities are working together to expand access to services 
for inadequately housed youth and for people living with mental health and substance use issues 
who require supportive housing.  
Alberta 
 As of March 28, 2018, Alberta has opened four supervised consumption services across the 
province, with another five anticipated to open in 2018–2019. The Lethbridge service is the first 
supervised consumption service in Canada to offer supervised inhalation; the Royal Alexandra 
Hospital in Edmonton is the first in-patient hospital supervised consumption service model in 
North America. 
 The Alberta naloxone program provides kits and overdose training distributed through harm 
reduction agencies, community-based organizations, pharmacies, emergency departments and 
Alberta Health Services facilities.  
 Alberta is developing an overdose prevention site program for both a fixed-term and short-term 
basis, which may include festivals and other community events.   
 Alberta has both launched a mainstream opioid awareness campaign by Alberta Health Service 
and provided grants to communities to increase awareness.  
 The College of Physicians and Surgeons of Alberta continues to communicate with physicians 
and the public about appropriate prescribing of opioids. 
 The College of Physicians and Surgeons of Alberta provides physicians who prescribe opioids 
and/or benzodiazepines with comparative prescribing pattern reports including a list of patients 
exceeding guidelines.  
 Alberta has been expanding access by opening many new treatment spaces in areas that were 
previously underserved. In addition, an opioid dependency advice line is available for physicians 
and prescribers to consult with an opioid dependence specialist for advice regarding prescribing 
drugs such as Suboxone and methadone, as well as treating patients with existing opioid 
dependency.  
 Alberta is implementing a supervised injectable opioid agonist therapy program in Edmonton and 
Calgary to support people with severe opioid use disorder. The program is planning to provide 
hydromorphone to clients.  
 Health Professional colleges have been making regulatory changes and releasing standards of 
practice to support healthcare professionals in providing opioid agonist therapy (e.g., the removal 
of administrative barriers for physicians prescribing Suboxone).  
Inventory of Best Practices along the Continuum of Care for the Treatment of Opioid Use Disorder  
Canadian Centre on Substance Use and Addiction  • Centre canadien sur les dépendances et l’usage de substances Page 21 
 Addiction Recovery and Community Health (ARCH) Team, in the Royal Alexandra Hospital 
(Edmonton), provides patient-centred, evidence-based and holistic care for patients with an 
active substance use disorder and/or those dealing with social inequity. ARCH is being expanded 
to both increase supports available to Edmonton clients and be implemented in Calgary. 
 A project to increase the role of primary care in the opioid response (i.e., improve access to 
opioid treatment in primary care) through a partnership of the College of Family Physicians, 
Alberta Medical Association, Alberta Health Services and the primary care networks.  
 Alberta is implementing a project where patients will be able to be initiated on Suboxone in 
emergency departments in Edmonton and Calgary.  
 Alberta is supporting Stimulus 2018, the national harm reduction and drug policy conference in 
Edmonton in October 2018. 
 Indigenous communities and Indigenous serving organizations were supported to develop and 
implement interventions to address the opioid crisis. 
Manitoba 
 Manitoba’s addiction services system offers a continuum of treatment services and support for 
youth and adults, including school-based intervention and prevention, medical and non-medical 
residential detoxification, a variety of community-based services, opiate replacement therapy 
clinics, short- and long-term specialized residential treatment, aftercare programming and 
outreach. 
 To assist Manitobans with finding the right service, the Manitoba Addictions Helpline was 
established in November 2015 and is operated by the Addictions Foundation of Manitoba.   
 Addictions services are provided by the Addictions Foundation of Manitoba, and a number of 
other organizations funded by Manitoba Health, Seniors and Active Living. 
 The health response to opioid use and misuse in Manitoba is being coordinated through a Health 
System Opioid Response. Work is managed to provide a system response in an integrated, 
coordinated and effective manner.   
 Accessibility to Suboxone has increased over the last year due to changes to the Manitoba Drug 
Formulary (removed coverage criteria for Suboxone to the Manitoba Pharmacare Program) and 
support of programs like the Manitoba Prescriber Education and Audit Program (MPEAP) 
 Effective April 20, 2017, Suboxone was moved from a Part 3 (Exception Drug Status) to a Part 1 
(open) listing on the Manitoba Drug Benefits Formulary making it easier for individuals to access 
coverage for this drug 
 Funding through the MPEAP has contributed to the development of an inter-professional “Opioids 
101” workshop, led by the College of Physicians and Surgeons of Manitoba. 
 A provincial naloxone distribution program was launched in January 2017. People who are at risk 
of opioid overdose may access free take-home naloxone kits at designated distribution sites 
located throughout the province. In addition they can receive overdose recognition and response 
training at participating distribution sites.  
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 As of September 30, 2017, there are 64 registered naloxone distribution sites, with registered 
sites in all five regional health authorities and First Nations. In the first nine months of 2017, 
over 765 take-home naloxone kits were distributed to people at risk of opioid overdose and over 
93 have been used in overdose events in the community. 
 Data collection has been improved through the implementation of a robust opioid surveillance 
system, which collects data from a wide range of stakeholders and provides analyses on the data 
to inform public health programming and direct policy. The Surveillance of Opioid Misuse and 
Overdose in Manitoba report is produced on a quarterly basis. 
http://www.gov.mb.ca/health/publichealth/surveillance/opioid.html 
 A social media awareness campaign was launched in November 2016 and a webpage created to 
provide information to the public and service providers about the dangers of fentanyl and how to 
get help. http://www.gov.mb.ca/health/mh/overdose/index.html 
 Information packages were sent to all schools in Manitoba, including First Nations schools, in 
November 2016. 
 A training manual was developed: Overdose Prevention, Recognition and Response. This manual 
provides education about the use of naloxone to address the morbidity and mortality associated 
with opioid overdoses. The manual is intended to prepare educators and trainers in provincial 
take-home naloxone distribution sites to prepare people to prevent, recognize and respond to 
overdose in a voluntary capacity. 
http://www.gov.mb.ca/health/publichealth/docs/training_manual_overdose.pdf  
 Increased funding from the Public Health Agency of Canada was received to increase harm 
reduction efforts.  
Ontario 
 Ontario has a range of services and supports that align with the continuum of care for the 
treatment of opioid use disorder.  
 The province has Assertive Community Treatment Teams that provide outreach and connections 
to treatment resources, and case management services that provide ongoing individual 
assessment and adjustment of treatment plans.  
 Individuals can access short-term treatment through Rapid Access Addiction Medicine clinics, 
which offer opioid agonist therapy, counselling, harm reduction interventions (e.g., naloxone kits) 
and advice, until they can be connected to longer-term support in their community.  
 Ontario has medical and non-medical withdrawal management services in residential and 
community-based settings, which offer additional supports such as discharge planning and early 
recovery education.  
 Both buprenorphine/naloxone and methadone are available pharmacological interventions for 
treating opioid use disorder on the Ontario Drug Benefit Formulary, and in April of 2017, nurse 
practitioners were given the ability to prescribe buprenorphine/naloxone to improve access to 
treatment.  
 The province offers psychosocial supports such as community-based lifestyle and personal 
counselling, including relapse prevention, which is available in individual, group and family 
formats, and individuals can access supportive housing services to aid in recovery.  
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 Ontario has addiction programs targeted to special populations, such as youth aged 12–24, 
Indigenous communities, and women, including pregnant women and mothers. 
 Treatment services are supported by initiatives to improve provider treatment capacity, including 
targeted outreach, training, and opioid agonist therapy prescribing support to interdisciplinary 
care teams in communities of high need through the Centre for Addiction and Mental Health, 
mentorship opportunities for treating opioid use disorder through the Ontario College of Family 
Physicians, and quality standards on treating opioid use disorder developed by Health Quality 
Ontario, released March 2018.  
 Ontario has various harm reduction initiatives such as needle exchange/syringe programs, 
naloxone distribution programs, supervised consumption services, and overdose prevention 
sites. Ontario’s three main programs where naloxone is made available at no cost to Ontarians to 
prevent opioid overdoses are the Ontario Naloxone Program (ONP), the take-home naloxone 
program for at-risk inmates in collaboration with the Ministry of Community Safety and 
Correctional Services, and the Ontario Naloxone Program for Pharmacies (ONPP).  The ministry 
maintains a list (in the form of a locator map) on its website that is available to the public and 
displays all of the organizations currently participating in the ONP and ONPP. This locator map 
can be found online at https://www.ontario.ca/page/get-naloxone-kits-free. The government has 
also strengthened the harm reduction workforce by providing new funding for the hiring of 
additional frontline harm reduction outreach workers and additional staff at public health units. 
 In the fall of 2017, the Ministry of Health and Long-Term Care established the Opioid Emergency 
Task Force that brings together representatives from province-wide system partners, including 
front-line workers in harm reduction, emergency response and addiction medicine, community 
mental health and addiction, education, public health, municipalities, primary care, hospitals, 
people with lived experience, as well as other essential partners, to strengthen the province’s 
coordinated response to the opioid crisis. 
 In December of 2017, Ontario launched the first phase of a robust and targeted public education 
campaign to raise awareness about the risks associated with both prescribed and illicit opioid 
use, and how people can protect themselves and their loved ones against addiction and 
overdose.    
New Brunswick 
 New Brunswick, currently has methadone maintenance treatment programs, which are also 
referred to as opioid replacement therapy programs. They are offered in different forms such as 
publicly funded, privately operated physician offices or specialized clinics. These services are 
now offered in most areas of the province. Individuals receiving opioid replacement therapy are 
able to also participate in various programs such as individual counselling and residential 
rehabilitation programs. 
 The accessibility to take-home naloxone kits is currently being rolled out in the province. The 
AIDS organizations through their needle exchange programs are able to provide take-home 
naloxone kits to those at risk. In addition, the residential withdrawal management programs 
(detox programs) will also be distributing the take-home naloxone kits to those most at risk.  
 The province has also increased their capacity to report on opioid-related data to get a better 
understand of the New Brunswick reality. The following website offers information and tools 
related to opioids: http://www2.gnb.ca/content/gnb/en/corporate/promo/opioids.html  
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 In addition, the following link provides surveillance data for our province. Last surveillance report 
available on the site: http://www2.gnb.ca/content/dam/gnb/Departments/h-
s/pdf/en/MentalHealth/New-Brunswick_opioid-surveillance-report_2017-Q3.pdf  
Newfoundland and Labrador 
 Newfoundland and Labrador has an integrated system of delivery for mental health and 
addictions. The province has prevention and promotion services, a youth outreach worker 
program and youth case managers. The province is looking at peer-support programming.  
 Under Towards Recovery Action Plan, Newfoundland and Labrador has an Action Plan for Mental 
Health and Addictions Services in the province. There are 54 recommendation to guide the re-
design of mental health and addictions services. These recommendations cross all points of the 
continuum.  
 In Newfoundland and Labrador, the four regional health authorities would offer mental health 
and addictions services. These services would differ from region to region; however, all regions 
would offer intake services, single-session counselling session (Doorways), and addictions 
counselling services (assessment and therapeutic counselling to individuals of all ages).   
 There is a Provincial Navigator who provides information on services via telephone for all 
regions.  
 There are three provincial inpatient addictions treatment programs:  
• Humberwood (Corner Brook) for 19+ 
• Grace Centre (Harbour Grace) for 18+  
• Hope Valley (Grand Falls) inpatient addictions treatment for 12–18 year olds.  
 Tuckamore: live in treatment program for 12–18 year olds with complex mental health needs 
 Withdrawal services  
• The Recovery Centre in St. John’s is open to anyone in the province who is 16+ and 
needs help while withdrawing from alcohol, drugs and/or gambling. This is a medical 
assisted withdrawal service.  
 Harm reduction  
• Take-home naloxone kits: available at 91 sites in the province  
• Safe Works Access program: offered through the NL AIDS Committee  
 Opioid Treatment Centre: St. John’s site  
 Methadone Clinic: Corner Brook  
 Mental Health Crisis Line and Gambling Line  
Yukon 
 No update to provide at this time 
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Nunavut 
Nunavut is currently not experiencing opioid-related harms to the same extent as other jurisdictions 
in Canada. As such, efforts are focused on naloxone availability and training sessions.   
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